NCT05019729View on ClinicalTrials.gov

Trial to Evaluate L9LS in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions
Malaria
Interventions
DRUG

VRC-MALMAB0114-00-AB

VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.

OTHER

Plasmodium falciparum (P. falciparum) sporozoite challenge

Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05019729 - Trial to Evaluate L9LS in Healthy Adults | Biotech Hunter | Biotech Hunter